• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: Which of the following is true about insulin products and the BPCIA?

Article

Many patient advocates hope that expansion of the Biologics Price Competition and Innovation Act (BPCIA) will bring further competition to the insulin market—and lower prices.

Which of the following is true about insulin products and the BPCIA?

The BPCIA now governs a large variety of insulin and human growth hormone products.
Many competing insulin products were established previously under the Hatch-Waxman Act.
Insulin prices have remained flat over the past decade.
Insulins are no more likely to receive interchangeable status than other biologics.

To find out more about insulins and the BPCIA, click here.

Recent Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Related Content
© 2024 MJH Life Sciences

All rights reserved.